论文部分内容阅读
目的观察阿德福韦酯联合拉米夫定治疗慢性乙型肝炎(乙肝)的临床效果。方法选择2015年6月-2016年6月收治的慢性乙肝患者84例,随机分为观察组和对照组各42例。对照组给予阿德福韦酯治疗,观察组在对照组基础上给予拉米夫定治疗,比较2组肝功能指标、乙型肝炎e抗原(HBeAg)转阴率、乙肝病毒脱氧核糖核酸(HBV-DNA)转移率和临床疗效。结果治疗前2组肝功能指标比较差异无统计学意义(P>0.05);治疗后2组患者丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)、血肌酐(SCr)水平均降低,且观察组低于对照组,差异均有统计学意义(P<0.05),观察组患者HBeAg、HBV-DNA转阴率高于对照组,差异有统计学意义(P<0.05)。观察组总有效率为92.86%高于对照组的73.81%,差异有统计学意义(P<0.05)。结论阿德福韦酯联合拉米夫定治疗慢性乙肝患者效果确切,有利于缓解临床症状,增强抗病毒效果,改善肝功能,提高治疗有效率,值得临床推广和应用。
Objective To observe the clinical effect of adefovir dipivoxil combined with lamivudine in the treatment of chronic hepatitis B (hepatitis B). Methods Eighty-four patients with chronic hepatitis B who were admitted to our hospital from June 2015 to June 2016 were randomly divided into observation group (42 cases) and control group (42 cases). The control group was treated with adefovir dipivoxil, and the observation group was treated with lamivudine on the basis of the control group. The liver function indexes, the negative rate of hepatitis B e antigen (HBeAg), the negative rate of hepatitis B virus deoxyribonucleic acid -DNA) metastasis rate and clinical efficacy. Results There was no significant difference in liver function between the two groups before treatment (P> 0.05). After treatment, ALT, AST, SCr (P <0.05). The negative rates of HBeAg and HBV-DNA in the observation group were higher than those in the control group (P <0.05), and the difference was statistically significant ). The total effective rate of the observation group was 92.86% higher than that of the control group (73.81%), the difference was statistically significant (P <0.05). Conclusion adefovir dipivoxil combined with lamivudine treatment of chronic hepatitis B patients with exact results, help to alleviate clinical symptoms, enhance anti-viral effect, improve liver function and improve the efficiency of treatment, it is worthy of clinical promotion and application.